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Introduction 
Horse or Zebra?  
The Common and Uncommon Presentations of CVID 
Jessica Telleria (Medical Student); Vishaal Sridhar (Medical Student); Joy Smith, MD 
•Common Variable Immunodeficiency 
(CVID) is the most frequently encountered 
primary immunodeficiency.  It consists of a 
group of heterogenous antibody deficiencies 
which most commonly predisposes patients 
to recurrent respiratory infections. However, 
some patients do present with other 
features of a weakened immune system 
such as autoimmune. diseases and/or 
malignancies.[1] 
•Disease of B cell differentiation failure. 
 
Patient Information 
1. 47 year old Hispanic male presents to 
the ED with three-day history of 
dyspnea, fever, chills and cough 
productive of clear sputum.  
2. No significant past medical history until 
the preceding year, when he was 
hospitalized 3-4 times with a diagnosis 
of pneumonia.  
3. He works as a truck driver traveling in 
the southwest United States, but 
primarily in Arizona.  
4. The patient reported temporary 
resolution of symptoms with each 
antibiotic treatment (name unknown). 
5. He also reports persistent conjunctivitis 
for the past year. 
6. He denies any significant childhood 
illness or hospitalization. 
7. He admits to two casual sexual contacts 
in the last year. 
 Admission  
•Temp 98.5 
•BP 74/46 
•HR 118 
•Dyspnea with extended conversation; 
diffuse coarse rhonchi with diminished air 
exchange in bilateral bases 
•Conjunctivae mildly injected with purulent 
matted discharge in the upper eyelashes 
•WBC 35,500 with predominance of 
neutrophils 
 
Timeline 
Day 1 
12/6 
• Initial Presentation 
• EKG shows ST elevation  
Day 2 
12/7 
• Initial workup and treatment for CAP  
 
Day 3 
12/8 
• ECHO shows pericardial tamponade 
• pericardial window  
• Hypogammaglobulinemia 
Day 6 
12/11 
• Pseudomonas on pericardial effusion culture 
• bone marrow bx and secondary workup (bx 
results negative for malignancy)  
Day 14 
12/19 
• Discharged on maxipime, IVIG q month 
Diagnostic Assessment 
•Serology: complement levels, 
Immunoglobulins, rheumatoid screen, 
Coccidiomycosis antibody, Histoplasma 
antibody, HIV screen negative, quantiferon 
negative 
•Bone marrow biopsy negative 
•EKG: diffuse ST elevations 
•ECHO: pericardial tamponade 
•Pericardial fluid culture: Pseudomonas 
•Sputum culture: respiratory flora 
•Urine culture: negative 
•Conjunctival fluid culture: normal flora 
•CXR: opacities at lung bases 
•Chest CT: bibasilar pneumonias, 
extensive mediastinal adenopathy, 
pericardial effusion 
Therapeutic Interventions 
•Pericardial window performed to alleviate 
pericardial tamponade. 
•IVIG infusions initiated during hospitalization.  
•Azactam given, then changed to Zosyn for 
Pseudomonas coverage.  
•Maxipime on discharge, with plan for monthly 
IVIG infusions.  
 
Follow Up Outcomes 
•Summarize clinical course of all 
follow up visits including 
      -Clinician and patient assessed 
outcomes 
       -Intervention adherance and 
tolerability 
       -Adverse and unanticipated 
events 
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Discussion  
•This case demonstrates the wide range of presentations with CVID. Quick diagnosis is 
imperative to avoid delays in treatment.  
Incidence 
•1:10,000 - 1:50,000 [2] 
•Equally affects both genders 
•34% of patients were diagnosed before the age of 10 
•Typical delay in diagnosis of 4-9 years [3]  
Common Presentations 
•CVID is the most common primary immunodeficiency. 
•It most commonly presents during puberty and young adulthood. 
•Although the presenting symptoms vary widely, it most commonly manifests itself as 
recurrent, bacterial, upper or lower respiratory tract infections. 
•Other presentations include conjunctivitis, GI infections, chronic lung disease, 
autoimmune disease, GI inflammatory disease, and malignancies 
•By definition, CVID causes low to absent levels of immunoglobulins, specifically IgG, 
IgA and/or IgM, in the absence of any other immunodeficiency state. As such, it is 
associated with poor response to immunizations. [4] 
Treatments 
•CVID is primarily treated with IVIG which has been shown to decrease pulmonary 
infections and hospitalizations. [5] 
•IVIG is given at a dose of 300 to 400mg/kg every 3-4 weeks. Trough IgG levels are 
measured every 6 months after the first dose. [5,6] 
•Higher doses can be given if patients have continued major infections or chronic lung 
disease. [6] 
•Patients on IVIG tend to remain susceptible to sinusitis and gastrointestinal infections. 
[7] 
•Infections should be treated with antibiotics. Other associated conditions (e.g. 
autoimmune disorders, enteropathies, granulomatous disorders) can be treated 
symptomatically. 
•Patients should receive age appropriate cancer screenings and must be monitored for 
malignancies including lymphoma and gastric cancer. [8,9,10] 
•Radiation exposure should be limited due to the elevated risk of developing 
malignancy 
•With the use of IVIG, the major causes of death are complications of chronic lung 
disease and malignancies, which can shorten the life span significantly (mean age: mid-
50’s). [11,12] 
 
